Michael J. Fisher

faculty photo
Associate Professor of Pediatrics at the Children's Hospital of Philadelphia
Attending Physician, Center for Childhood Cancer Research and Division of Oncology, Children's Hospital of Philadelphia
Chair, Clinical Research Quality Assurance Committee, Center for Childhood Cancer Research and Division of Oncology, Children’s Hospital of Philadelphia
Director, Neurofibromatosis Program, Children’s Hospital of Philadelphia
Department: Pediatrics

Contact information
Center for Childhood Cancer Research and Division of Oncology
The Children’s Hospital of Philadelphia
Colket Translational Research Building - 10th Floor
3501 Civic Center Blvd
Philadelphia, PA 19104
Office: (215)590-2800

Eberhard-Karls Universitaet, Tubingen, Germany, 1987.
B.A. (Psychology, Summa cum Laude)
Amherst College, 1989.
Harvard Medical School (cum Laude), 1994.
Permanent link

Description of Itmat Expertise

Dr. Fisher is interested in the management of brain tumors and tumors related to neurofibromatosis type 1 and in new imaging modalities for evaluation of plexiform neurofibromas and brain tumors.

Selected Publications

Gurney JG, Bass JK, Onar-Thomas A, Huang J, Chintagumpala M, Bouffet E, Hassall T, Gururangan S, Heath J, Kellie S, Cohn R, Fisher MJ, Pai-Panandikar A, Merchant TE, Srinivasan A, Wetmore C, Qaddoumi I, Stewart CF, Armstrong GT, Broniscer A, Gajjar A. : Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average risk or high risk medulloblastoma. Neuro-Oncology 16(6): 848-855, 2014.

Widemann B, Acosta M, Ammoun S, Belzberg A, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp W, Dombi E, Evans GD, Ferner R, Fernandez-Valle C, Fisher MJ, Giovanini M, Gutmann D, Hanemann O, Hennigan R, Huson S, Ingram D, Kissil J, Korf B, Legius E, Packer RJ, McClatchey A, McCormick F, North K, Pehrsson M, Plotkin S, Ramesh V, Ratner N, Schirmer S, Sherman L, Shorry E, Stevenson D, Stewart D, Ullrich N, Annette C. Bakker AC, Helen Morrison H: CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and Schwannomatosis towards the development of effective therapies. Am J Med Genet A 164A(3): 563-578, 2014.

Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, D'Agostino McGowan L, Liu GT: Gender as a Disease Modifier in Neurofibromatosis Type 1 Optic Pathway Glioma. Annals of Neurology 75(5): 799-800, 2014.

Bass JK, Huang J, Onar-Thomas A, Chang KW, Bhagat SP, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Heath JA, McCowage G, Cohn RJ, Fisher MJ, Robinson G, Broniscer A, Gajjar A, Gurney JG: Concordance between the Chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatric Blood & Cancer 61(4): 601–605, 2014.

Weiss B, Widemann BC, Wolters P, Dombi E, Vinks AA, Cantor A, Korf B, Perentesis J, Gutmann DH, Schorry E, Packer R, Fisher MJ: Sirolimus for non-Progressive NF1-Associated Plexiform Neurofibromas: An NF Clinical Trials Consortium Phase II Study. Pediatric Blood & Cancer 61: 982–986, 2014.

Delgado J, Jaramillo D, Ho-Fung V, Fisher MJ, Anupindi SA: MRI features of plexiform neurofibromas involving the liver and pancreas in children with Neurofibromatosis Type 1 Clinical Radiology 69(6): e280-284, 2014.

de Blank P, Cole K, Kersun L, Green A, Wilkes JJ, Belasco J, Bagatell R, Bailey LC, Fisher MJ : FDG-PET in two cases of neurofibromatosis type 1 and atypical malignancies. Current Oncology 21(2): e345-348, 2014.

Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, Rood BR, Packer RJ: Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatric Blood & Cancer 60(5): 776-782, September 2013.

de Blank PMK, Berman JI, Liu GT, Roberts TP, Fisher MJ: Fractional Anisotropy of the Optic Radiations is Associated with Visual Acuity Loss in Optic Pathway Gliomas of Neurofibromatosis Type 1. Neuro-Oncol 15(8): 1088-95, August 2013.

Scott JR, Courter JD, Saldaña SN, Widemann BC, Fisher M, Weiss B, Perentesis J, Vinks AA : Population Pharmacokinetics of Sirolimus in Pediatric Patients With Neurofibromatosis Type 1. Ther Drug Monit 35(3): 332-337, June 2013.

back to top
Last updated: 10/19/2014
The Trustees of the University of Pennsylvania